Department of Pharmacology, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Chin J Integr Med. 2012 Apr;18(4):250-2. doi: 10.1007/s11655-012-1063-5. Epub 2012 Mar 30.
Chronic kidney disease (CKD) and chronic liver disease are both very harmful to human health almost all over the world, which lead to the fibrosis of the two organs ultimately. Currently, there are few satisfactory therapeutic methods in treating the two diseases. Some research works from Chinese medicine and Western medicine were done in the area recently, the results showed that kidney and liver fibrosis shared similar biological signals and events such as epithelial-mesenchymal transition (EMT) and transforming growth factor β 1, the same herbal mesenchymal medicine exhibited significantly improving effects on both liver fibrosis and kidney fibrosis by involving similar mechanism. This coincides with the theory of homogeny of Liver (Gan) and Kidney (Shen) of Chinese medicine. It would provides new clues in exploring the treatment of liver fibrosis and kidney fibrosis.
慢性肾脏病(CKD)和慢性肝病在全球范围内都对人类健康造成极大危害,最终导致这两个器官的纤维化。目前,这两种疾病的治疗方法还很少令人满意。最近在中医和西医领域都做了一些相关研究工作,结果表明,肾和肝纤维化具有相似的生物学信号和事件,如上皮-间充质转化(EMT)和转化生长因子β 1,同样的草药间充质药物通过涉及相似的机制,对肝纤维化和肾纤维化均有显著改善作用。这与中医的“肝(Gan)肾(Shen)同源”理论相符。这为探索肝纤维化和肾纤维化的治疗方法提供了新的线索。